cofounder @NoriDotAi (YC F25). prev: product director @spotify 💚 cofounder https://nitter.cf/t.co/8KupTBNMpo (acq @spotify) 📈 @AngelList 🎧 always listening
ny
Joined May 2007
- Tweets2.5K
- Following1.3K
- Followers4.3K
- Likes5.2K
Dave Zohrob 📈 retweeted
Today, we're excited to announce that we have raised $10 million in funding and officially launched Sava Trust Company, an AI-native, modern trust company chartered in Nevada, open to clients and their attorneys & advisors nationwide.
Our funding was led by @GradientVC, with participation from @ycombinator, @svangel, @Max, @orangecollectv and @SurgePointCap.
For too long, trust administration has relied on manual processes, disconnected systems, and complex fee structures. Establishing a trust can take weeks or months, with limited visibility for families and their advisors over the life of the trust.
With Sava, we're building a better way.
youtube.com/watch?v=yR2bV3KT…
Dave Zohrob 📈 retweeted
Introducing Polly 🦜
Polly ships this fall. The app behind Polly:
1. 2.1M lessons completed, 2.3M+ min of Spanish immersed (4 years of Spanish immersion)
2. 31 min avg session (Instagram's global avg is 35)
3. Power users doing 5.5+ hrs/day
4. 620K+ learners
Get your own Polly. Link below.
Dave Zohrob 📈 retweeted
Today @fambotAI announced we’ve closed a $3.5M pre-seed co-led by @NextViewVC and @_baukunst , 1,000+ families, apps live on iOS + Android, and WhatsApp integration. Fambot is AI that exists to let parents put their phones down and be present with their kids - free in beta
Proud to be a (small) angel in Pocket! Great product.
8 months ago, we shipped the first Pocket. Today, 100,000 people use it to be present in their most important conversations.
Grateful to have @Accel, @peakxvpartners, @ycombinator, @rauchg, @mati, and @nejatian behind us for what comes next.
Dave Zohrob 📈 retweeted
Making a strategic acquisition as a seed-stage company was not a decision I took lightly, but so far all I'm wondering is why we didn't do this sooner.
We first met the Keypo folks about 6 months ago during the YC batch, and were blown away by not only their alignment on highly complementary problems in the agent security space, but more importantly the strong common principles and values that underpin both of our companies.
Behind the scenes, we've been working with Dave full-time for about a month while the acquisition was being finalized, and immediately noticed a boost in energy and productivity across our entire team.
Dave's background and experience in security, authentication, AI agents, and trusted hardware is unparalleled. He's been an absolute pleasure to work with so far, and I'm so excited to share updates about what we're building together in the coming weeks and months.
many thanks to @EverywhereVC for allowing me to talk about our big plans for Nori @NoriDotAI in their newsletter this week (and my obsession with Elena Ferrante)
our North Star is to add a billion healthy years of living to humanity - and we're just getting started 💚
💪🏾We all want to be healthier and Nori.ai is helping make that happen. It’s a personal health agent that learns from your wearable + health data, then proactively nudges you to keep you on track.
Co-founder & CEO @dzohrob shares more: ideas.everywhere.vc/p/nori-d…
ALT A company profile card for Nori with a magenta header displaying the mirrored “EVERYWHERE” Ventures logo. On the left, the Nori logo appears above the label “Health” and the description: “Personal health agent that helps you get healthier, whatever it takes — using your own data, wearables, and the apps you already use.” The website “NORI.AI” is listed below. On the right, there is a circular black‑and‑white portrait labeled “Dave Zohrob, CEO, CO‑FOUNDER.
Dave Zohrob 📈 retweeted
Announcing @LeadbayAI $4.3M to kill everything you're doing with sales.
Corgi, Deel, L'Oréal recently told us: "We found in 10 min on Leadbay what we couldn't in 6 months with Clay and a GTM agency."
Leadbay qualifies the millions of data-signal-scarce companies nobody could find before.
This is how it works:
Congrats to @flickartHQ on the raise - happy to back this amazing team!
We raised $6M to bring the future of filmmaking into your hands. Today, the premiere of our first Flick Residency Film Series is now live.
14 filmmakers. 13 films. All made on Flick.
Founded by filmmaker @ZoeyZ1004 and Instagram Stories founding engineer @RuiCromwell . Backed by @trueventures , @GVteam , @ycombinator (@garrytan , @golda ), @lightspeedvp, @pioneer_fund, Formosa Capital, @OliveTreeCap , and N1.
Dave Zohrob 📈 retweeted
we just shipped something i'm really proud of:
Nori 2.0, your personal health agent
Dave Zohrob 📈 retweeted
Many "best practices" are rightfully being questioned
(from @dzohrob's re-introduction to Nori)
Nori helps you get healthier, whatever it takes— using your own data, wearables, and the apps you already use.
every interaction makes Nori better for you, and helps us learn what actually works for behavior change
wrote up some thoughts on what we got wrong with nori 1.0 here, and why we're so excited about 2.0: nori.ai/blog/what-everyone-g…
would love to hear your feedback! sign up: nori.ai
Congrats to @rrhoover and @vedikaja_in — I'm proud to be a (small) backer of Fund III and Fund IV :)
Announcing Weekend Fund IV, backed by operators and founders (and maybe you).
When we raised Weekend Fund III, we did something different.
Toward the end of our raise, we announced the fund in public and accepted applications from LPs.
Our goal was to make early-stage venture more accessible and align ourselves with an army of operators and founders to help us and the startups we back.
Over 1,000 people expressed interest to join and hundreds did, but there was a problem. Legally, only accredited investors could participate as an LP. Accreditation laws are well-meaning but limit access to the majority of consumers.
With WF IV, @vedikaja_in and I are doing something different.
Like before, we’re onboarding engineers, designers, researchers, data scientists, salespeople, and other domain experts as LPs in the fund. But this time at a larger scale with USVC.
AngelList recently announced USVC, a new kind of fund that’s accessible to everyone, including the non-accredited. It holds positions in private late-stage companies like xAI, Anthropic, OpenAI, Sierra, and Vercel. I personally invested.
Today, they just announced their investment in Weekend Fund IV, one of the first early-stage funds added to their portfolio.
If you’re interested in being a part of Weekend Fund and getting exposure to generational startups mentioned above, visit usvc [dot] com.
Of course, don’t invest what you can’t afford to lose.
Investing in startups is risky and you may lose all your money. USVC shares are illiquid with no guarantee of repurchase.
Consider investment objectives, risks, charges and expenses carefully before investing. Read the prospectus: usvc [dot] com/prospectus.
Also, USVC is currently limited to US citizens. They’re working to open the fund to other geographies.
Lastly, my DMs are open. :)
Dave Zohrob 📈 retweeted
I'm lucky enough to have a great doctor and access to excellent Bay Area medical care. I've taken lots of standard screening tests over the years and have tried lots of "health tech" devices and tools.
With all this said, by far the most useful preventative medical advice that I've ever received has come from unleashing coding agents on my genome, having them investigate my specific mutations, and having them recommend specific follow-on tests and treatments.
Population averages are population averages, but we ourselves are not averages. For example, it turns out that I probably have a 30x(!) higher-than-average predisposition to melanoma. Fortunately, there are both specific supplements that help counteract the particular mutations I have, and of course I can significantly dial up my screening frequency. So, this is very useful to know.
I don't know exactly how much the analysis cost, but probably less than $100. Sequencing my genome cost a few hundred dollars.
(One often sees papers and articles claiming that models aren't very good at medical reasoning. These analyses are usually based on employing several-year-old models, which is a kind of ludicrous malpractice. It is true that you still have to carefully monitor the agents' reasoning, and they do on occasion jump to conclusions or skip steps, requiring some nudging and re-steering. But, overall, they are almost literally infinitely better for this kind of work than what one can otherwise obtain today.)
There are still lots of questions about how this will diffuse and get adopted, but it seems very clear that medical practice is about to improve enormously. Exciting times!